NCT01393717View on ClinicalTrials.gov

Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

October 20, 2011

Primary Completion Date

February 1, 2017

Study Completion Date

February 1, 2017

Conditions
Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma
Interventions
DRUG

brentuximab vedotin

Given IV

Trial Locations (2)

10065

Weill Medical College, Cornell University, New York

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT01393717 - Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter